Botox approved for chronic migraine in UK
Botox receives approval for chronic migraine
Today, 9 July, the British Medicines and Healthcare Regulatory Agency granted approval for the use of Botox® botulinum toxin A for use in the treatment of chronic migraine. It is estimated that this condition affects about 700,000 people in the UK. The drug must still face regulatory hurdles with the National Institute for Clinical Excellence, which must now determine whether it offers value for cost.
This is, however, the world's first regulatory body to approve botulinum toxin for the treatment of chronic migraine, defined as headaches at least 15 days a month, and of which at least 8 days are migraine.
Chronic migraine affects about 2% of the US population, and contributes to substantial disability and reduced productivity due to headache pain. Botox® is awaiting US FDA approval for use in the treatment of chronic migraine.